

# Myositis - Pipeline Insight, 2021

<https://marketpublishers.com/r/MD09D51C599CEN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: MD09D51C599CEN

## Abstracts

This report can be delivered to the clients within 3-5 business days

DelveInsight's, "Myositis - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Myositis Understanding

#### Myositis: Overview

The term "myositis" refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest. Other conditions that can cause muscle weakness and pain include infection, muscle injury from medications, inherited diseases, electrolyte imbalances, and thyroid disease. More often, however, the term myositis is used to refer to a disease involving chronic inflammation of the muscles, often occurring together with other symptoms. This condition is also known as idiopathic inflammatory myopathy (IIM). The disease is highly variable and has been classified into a number of forms, including: Dermatomyositis (DM), Polymyositis (PM), Necrotizing myopathy (NM), Sporadic inclusion body myositis (sIBM), Juvenile forms of myositis (JM). Myositis is often difficult to diagnose, because many physicians are unfamiliar with the disease

and its symptoms. A typical diagnosis process for myositis patients begins with a medical history and physical examination. It may also include blood tests, muscle and skin biopsies, and a variety of other diagnostic tests.

'Myositis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myositis pipeline landscape is provided which includes the disease overview and Myositis treatment guidelines. The assessment part of the report embraces, in depth Myositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myositis R&D. The therapies under development are focused on novel approaches to treat/improve Myositis.

### Myositis Emerging Drugs Chapters

This segment of the Myositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Myositis Emerging Drugs

#### Lenabasum: Corbus Pharmaceuticals

Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing

to date, lenabasum has acceptable safety and tolerability profiles.

Belimumab: GlaxoSmithKline

Belimumab is a fully human monoclonal antibody that has been developed by GlaxoSmithKline/MedImmune for the treatment of autoimmune disorders. Currently, it is in Phase II stage of development to treat Myositis.

Further product details are provided in the report.

Myositis: Therapeutic Assessment

This segment of the report provides insights about the different Myositis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myositis

There are approx. 15+ key companies which are developing the therapies for Myositis. The companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myositis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myositis therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myositis drugs.

### Myositis Report Insights

- Myositis Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

### Myositis Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

### Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Myositis drugs?

How many Myositis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myositis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myositis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Myositis and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

GlaxoSmithKline

Corbus Pharmaceuticals

Abcuro, Inc.

Orphazyme

Bristol-Myers Squibb

Kezar Life Sciences, Inc.

Viela Bio

Paeon Biotechnology Inc.

Alexion Pharmaceuticals

Janssen Biotech

CSL Behring

Pfizer

Restem, LLC.

Roche

### Key Products

Belimumab

Lenabasum

ABC008

Abatacept

KZR-616

MEDI7734

PN-101

Ravulizumab

tocilizumab

PF-06823859

Ustekinumab

## Contents

Introduction

Executive Summary

Myositis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Myositis – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Lenabasum: Corbus Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

KZR-616: Kezar Life Sciences

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

ABC 008: Abcuro

Product Description



Research and Development  
Product Development Activities  
Drug profiles in the detailed report.  
Inactive Products  
Comparative Analysis  
Myositis Key Companies  
Myositis Key Products  
Myositis- Unmet Needs  
Myositis- Market Drivers and Barriers  
Myositis- Future Perspectives and Conclusion  
Myositis Analyst Views  
Myositis Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for Myositis
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for Myositis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: Myositis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/MD09D51C599CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MD09D51C599CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970